A Phase 2 interventional study of RO6889450 and Placebo in Schizophrenia, Schizoaffective Disorder, sponsored by Hoffmann-La Roche. Terminated at 45 sites in 4 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-08-12.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.
Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 11th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 in phase 2, and was the 17th registered.
3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.
Browse Schizophrenia studies →None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →
Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2018.
This study's enrollment of 131 is above the median of 71 across 2,947 interventional studies indexed under Schizophrenia.
Median enrollment 294 across the 16 interventional studies, 1,431 across the 3 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Schizophrenia by Hoffmann-La Roche, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive RO6889450 or a dose-matched placebo. NOTE: Part A has completed enrollment.
Drug: RO6889450 · Drug: Placebo
Participants will receive a low or high dose of RO6889450 or a dose-matched placebo in addition to their usual anti-psychotic treatment(s).
Drug: RO6889450 · Drug: Placebo
Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
Brief Negative Symptoms Scale (BNSS) Avolition/Apathy Subscore and Total Score at Baseline and Week 12
The BNSS is a 13-item instrument designed for clinical trials that measures the severity of the negative symptoms of schizophrenia in five domains. There are 13 items organized into 6 subscales (anhedonia, distress, asociality, avolition, blunted affect, and alogia), each rated on a 7-point scale (0-6) where 0 = absent symptoms and 6 = severe symptoms. The total score is calculated by summing the individual items (13) of each subscale and has a range of 0-78. The avolition/apathy subscale contains 2 items with a total score range of 0-12.
Time frame: Baseline to Week 12
Clinical Global Impression Severity (CGI-S) Overall Scores
The CGI-S is an absolute measure assessing how mentally ill the participant is at the time of the assessment on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). On the scale, the value 0 corresponds to 'not assessed', which will be excluded from the analyses. The values 1 to 7 will be transformed into the 0 to 6 range prior to statistical analysis for the question on the measure ("Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?"), making the total score range 0-6.
Time frame: Baseline to week 12
CGI-S Negative Symptoms (NS) Scores
The CGI-S-NS is similar to the CGI-S and is assessed on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). On the scale, the value 0 corresponds to 'not assessed', which will be excluded from the analyses. The values 1 to 7 will be transformed into the 0 to 6 range prior to statistical analysis for the question on the measure, making the total score range 0-6.
Time frame: Baseline to week 12
Clinical Global Impression - Improvement (CGI-I) Overall Scores
The CGI-I assesses how much the participant's condition has changed at the time of the assessment in comparison to their condition at baseline. It uses a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), where the value 0 corresponds to 'not assessed' and will be excluded from any analyses.
Time frame: Up to Week 12 (Day 84)
CGI-I Negative Symptoms Scores
The CGI-I NS is similar to the CGI-I and assesses how much the participant's condition has changed at the time of the assessment in comparison to their condition at baseline. It uses a 7-point scale, where: 1. = Very much improved 2. = Much improved 3. = Minimally improved 4. = No change 5. = Minimally worse 6. = Much worse 7. = Very much worse
Time frame: Up to Week 12 (Day 84)
Positive and Negative Syndrome Scale (PANSS) Total Scores
The PANSS Marder factors examine schizophrenia symptoms in five domains: positive symptoms, negative symptoms, disorganized thought, uncontrolled hostility/excitement, and depression/anxiety. The Marder factor positive symptom score (range = 8-56) measures responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12) while the negative symptom factor score (range = 7-49) consists of 7 items (N1,N2,N3,N4,N6,G7,G16). Each item is scored on a scale of 1-7, where 1 = an absence of symptoms and 7 = extreme symptoms. The positive and negative syndrome scale total score is the sum of the scores from each domain (range = 15-105); higher scores indicate greater severity of symptoms.
Time frame: Baseline to week 12
PANSS Symptom Factor Scores
The PANSS Marder factors examine schizophrenia symptoms in five domains: positive symptoms, negative symptoms, disorganized thought, uncontrolled hostility/excitement, and depression/anxiety. The Marder factor positive symptom score (range = 8-56) measures responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12) while the negative symptom factor score (range = 7-49) consists of 7 items (N1,N2,N3,N4,N6,G7,G16). Each item is scored on a scale of 1-7, where 1 = an absence of symptoms and 7 = extreme symptoms.
Time frame: Baseline to week 12
Brief Negative Symptom Scale (BNSS) Total Scores
The BNSS is a 13-item instrument designed for clinical trials that measures the severity of the negative symptoms of schizophrenia in five domains. There are 13 items organized into 6 subscales (anhedonia, distress, asociality, avolition, blunted affect, and alogia), each rated on a 7-point scale (0-6) where 0 = absent symptoms and 6 = severe symptoms. The total score is calculated by summing the individual items (13) of each subscale and has a range of 0-78.
Time frame: Baseline to week 12
Defeatist Performance Attitude Scale (DPAS) Scores
The DPAS is a 15-item, patient-rated assessment that evaluates expectations of failures or self-defeating beliefs related to prior failed experiences as well as illness on a 7-point Likert scale (total range = 15-105) ranging from totally agree (1) to totally disagree (7).
Time frame: Baseline to week 12
Number of Participants With Suicidal Ideation or Behavior, and Self-injurious Behavior Without Suicidal Intent on the Columbia Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a suicide risk assessment tool used to help identify the risk of suicide.
Time frame: Baseline through Day 84
Extrapyramidal Symptom Rating Scale, Abbreviated (ESRS-A)
The ESRS-A is used to evaluate the presence and severity of extrapyramidal symptoms. Items are rated on a scale of 0 (no symptoms) to 5 (extreme symptoms).
Time frame: Baseline through Day 84
Maximum Serum Concentration (Cmax) of RO6889450
Time frame: Day 42
Area Under the Curve at Steady State (AUCss) of RO6889450
Time frame: Day 42
| Milestone | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Started | 15 | 12 | 37 | 5 | 30 | 32 |
| Completed | 10 | 7 | 33 | 5 | 27 | 29 |
| Not completed | 5 | 5 | 4 | 0 | 3 | 3 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 | 0 | 1 | 3 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Disease relapse | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 1 | 0 | 0 | 1 | 0 |
The BNSS is a 13-item instrument designed for clinical trials that measures the severity of the negative symptoms of schizophrenia in five domains. There are 13 items organized into 6 subscales (anhedonia, distress, asociality, avolition, blunted affect, and alogia), each rated on a 7-point scale (0-6) where 0 = absent symptoms and 6 = severe symptoms. The total score is calculated by summing the individual items (13) of each subscale and has a range of 0-78. The avolition/apathy subscale contains 2 items with a total score range of 0-12.
| Units on a scale | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Baseline Avolition/Apathy Subscore | 5.71 ± 2.81 | 5.50 ± 2.71 | 6.0 ± 2.3 | 6.2 ± 1.3 | 5.8 ± 1.9 | 5.9 ± 2.4 |
| Week 12 (Day 84) Avolition/Apathy Subscore | 5.50 ± 2.55 | 4.67 ± 3.27 | 5.0 ± 1.9 | 5.3 ± 1.0 | 4.1 ± 2.1 | 4.7 ± 2.1 |
The CGI-S is an absolute measure assessing how mentally ill the participant is at the time of the assessment on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). On the scale, the value 0 corresponds to 'not assessed', which will be excluded from the analyses. The values 1 to 7 will be transformed into the 0 to 6 range prior to statistical analysis for the question on the measure ("Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?"), making the total score range 0-6.
| Units on a scale | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Baseline | 3.600 ± 0.507 | 3.667 ± 0.492 | 4.1 ± 0.7 | 3.8 ± 0.4 | 3.9 ± 0.7 | 4.0 ± 0.7 |
| Day 14 | 3.467 ± 0.516 | 3.700 ± 0.483 | 4.0 ± 0.6 | 3.8 ± 0.5 | 3.8 ± 0.6 | 4.0 ± 0.8 |
| Day 28 | 3.500 ± 0.527 | 3.333 ± 0.500 | 3.9 ± 0.8 | 3.8 ± 0.5 | 3.8 ± 0.6 | 3.7 ± 0.7 |
| Day 42 | 3.636 ± 0.809 | 3.375 ± 0.744 | 3.8 ± 0.8 | 3.8 ± 0.5 | 3.6 ± 0.6 | 3.6 ± 0.7 |
| Day 56 | 3.636 ± 0.505 | 3.143 ± 0.378 | 3.8 ± 0.8 | 3.8 ± 0.5 | 3.5 ± 0.7 | 3.5 ± 0.8 |
| Day 70 | 3.500 ± 0.707 | 3.143 ± 0.690 | — | — | — | — |
| Day 84 | 3.700 ± 0.483 | 3.000 ± 0.632 | 3.7 ± 0.8 | 3.8 ± 0.5 | 3.4 ± 0.6 | 3.5 ± 0.7 |
The CGI-S-NS is similar to the CGI-S and is assessed on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). On the scale, the value 0 corresponds to 'not assessed', which will be excluded from the analyses. The values 1 to 7 will be transformed into the 0 to 6 range prior to statistical analysis for the question on the measure, making the total score range 0-6.
| Units on a scale | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Baseline | 3.867 ± 0.743 | 3.917 ± 0.669 | 4.4 ± 0.6 | 4.2 ± 0.4 | 4.3 ± 0.7 | 4.3 ± 0.7 |
| Day 14 | 3.600 ± 0.632 | 3.800 ± 0.632 | 4.3 ± 0.7 | 4.3 ± 0.5 | 3.9 ± 0.7 | 4.1 ± 0.7 |
| Day 28 | 3.800 ± 0.632 | 3.778 ± 0.667 | 4.1 ± 0.8 | 4.3 ± 0.5 | 3.8 ± 0.7 | 3.9 ± 0.7 |
| Day 42 | 3.727 ± 0.467 | 3.625 ± 0.518 | 3.9 ± 0.9 | 4.0 ± 0.0 | 3.8 ± 0.7 | 3.7 ± 0.7 |
| Day 56 | 3.636 ± 0.674 | 3.714 ± 0.756 | 3.9 ± 0.8 | 4.0 ± 0.0 | 3.6 ± 0.7 | 3.5 ± 0.7 |
| Day 70 | 3.500 ± 0.527 | 3.286 ± 0.756 | — | — | — | — |
| Day 84 | 3.400 ± 0.516 | 3.167 ± 0.753 | 3.9 ± 0.8 | 3.8 ± 0.5 | 3.4 ± 0.6 | 3.5 ± 0.9 |
The CGI-I assesses how much the participant's condition has changed at the time of the assessment in comparison to their condition at baseline. It uses a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), where the value 0 corresponds to 'not assessed' and will be excluded from any analyses.
| Units on a scale | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Day 14 | 3.71 ± 0.91 | 3.56 ± 0.53 | 3.7 ± 0.4 | 4.0 ± 0.0 | 3.6 ± 0.5 | 3.6 ± 0.6 |
| Day 21 | 4.00 ± NA | 2.00 ± NA | — | — | — | — |
| Day 28 | 3.56 ± 0.73 | 3.50 ± 0.76 | 3.5 ± 0.7 | 4.0 ± 0.0 | 3.5 ± 0.8 | 3.4 ± 0.8 |
| Day 35 | 3.50 ± 0.71 | — | — | — | — | — |
| Day 42 | 3.73 ± 0.65 | 3.29 ± 0.76 | 3.4 ± 0.7 | 3.8 ± 0.5 | 3.3 ± 0.8 | 3.3 ± 0.9 |
| Day 56 | 3.70 ± 0.48 | 3.14 ± 0.69 | 3.4 ± 0.7 | 3.8 ± 0.5 | 3.4 ± 0.9 | 3.1 ± 1.0 |
| Day 70 | 3.50 ± 0.71 | 2.86 ± 0.90 | — | — | — | — |
| Day 84 | 3.80 ± 0.42 | 3.00 ± 0.63 | 3.2 ± 0.7 | 3.8 ± 0.5 | 3.0 ± 0.9 | 3.0 ± 1.0 |
The CGI-I NS is similar to the CGI-I and assesses how much the participant's condition has changed at the time of the assessment in comparison to their condition at baseline. It uses a 7-point scale, where: 1. = Very much improved 2. = Much improved 3. = Minimally improved 4. = No change 5. = Minimally worse 6. = Much worse 7. = Very much worse
| Units on a scale | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Day 14 | 3.71 ± 0.61 | 3.44 ± 0.73 | 3.7 ± 0.5 | 4.0 ± 0.0 | 3.5 ± 0.6 | 3.5 ± 0.6 |
| Day 21 | 5.00 ± NA | 4.00 ± NA | — | — | — | — |
| Day 28 | 3.44 ± 0.73 | 3.38 ± 0.74 | 3.5 ± 0.7 | 4.0 ± 0.0 | 3.3 ± 0.7 | 3.2 ± 0.8 |
| Day 35 | 4.50 ± 0.71 | — | — | — | — | — |
| Day 42 | 3.45 ± 0.69 | 3.43 ± 0.79 | 3.3 ± 0.6 | 3.5 ± 0.6 | 3.3 ± 0.8 | 3.2 ± 0.8 |
| Day 56 | 3.50 ± 0.71 | 3.43 ± 0.53 | 3.2 ± 0.7 | 3.5 ± 0.6 | 3.2 ± 0.8 | 2.9 ± 0.8 |
| Day 70 | 3.40 ± 0.70 | 3.00 ± 0.82 | — | — | — | — |
| Day 84 | 3.10 ± 0.74 | 2.83 ± 0.41 | 3.1 ± 0.7 | 3.0 ± 0.8 | 2.9 ± 0.9 | 2.8 ± 0.9 |
The PANSS Marder factors examine schizophrenia symptoms in five domains: positive symptoms, negative symptoms, disorganized thought, uncontrolled hostility/excitement, and depression/anxiety. The Marder factor positive symptom score (range = 8-56) measures responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12) while the negative symptom factor score (range = 7-49) consists of 7 items (N1,N2,N3,N4,N6,G7,G16). Each item is scored on a scale of 1-7, where 1 = an absence of symptoms and 7 = extreme symptoms. The positive and negative syndrome scale total score is the sum of the scores from each domain (range = 15-105); higher scores indicate greater severity of symptoms.
| Units on a scale | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Baseline | 67.43 ± 9.35 | 67.92 ± 10.86 | 71.4 ± 10.3 | 62.8 ± 6.7 | 69.6 ± 11.1 | 67.8 ± 11.1 |
| Day 14 | 68.38 ± 10.37 | 69.00 ± 11.40 | 67.3 ± 8.5 | 69.5 ± 13.5 | 67.4 ± 10.5 | 67.9 ± 13.6 |
| Day 28 | 66.10 ± 10.38 | 65.44 ± 7.30 | 67.0 ± 10.9 | 81.3 ± 4.7 | 66.8 ± 11.4 | 66.5 ± 11.1 |
| Day 42 | 70.09 ± 10.88 | 65.88 ± 12.01 | 68.3 ± 12.7 | 73.3 ± 9.8 | 61.8 ± 10.9 | 64.1 ± 12.5 |
| Day 56 | 66.60 ± 8.13 | 61.14 ± 6.91 | 64.3 ± 11.7 | 70.0 ± 7.1 | 63.2 ± 14.4 | 61.4 ± 11.7 |
| Day 70 | 68.50 ± 7.65 | 59.57 ± 7.14 | — | — | — | — |
| Day 84 (Week 12) | 64.70 ± 13.92 | 59.17 ± 6.27 | 64.4 ± 12.2 | 74.8 ± 7.2 | 59.0 ± 11.1 | 60.9 ± 11.3 |
The PANSS Marder factors examine schizophrenia symptoms in five domains: positive symptoms, negative symptoms, disorganized thought, uncontrolled hostility/excitement, and depression/anxiety. The Marder factor positive symptom score (range = 8-56) measures responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12) while the negative symptom factor score (range = 7-49) consists of 7 items (N1,N2,N3,N4,N6,G7,G16). Each item is scored on a scale of 1-7, where 1 = an absence of symptoms and 7 = extreme symptoms.
| Units on a scale | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Baseline - Negative symptoms | 21.29 ± 4.45 | 21.00 ± 5.20 | 23.0 ± 4.7 | 20.6 ± 3.3 | 23.3 ± 4.7 | 23.5 ± 4.1 |
| Day 14 - Negative symptoms | 22.46 ± 5.13 | 20.40 ± 3.95 | 22.9 ± 3.4 | 20.8 ± 2.9 | 21.8 ± 4.5 | 22.2 ± 5.3 |
| Day 28 - Negative symptoms | 18.40 ± 6.67 | 20.44 ± 3.68 | 20.9 ± 4.8 | 20.3 ± 3.1 | 21.5 ± 4.0 | 22.1 ± 4.9 |
| Day 42 - Negative symptoms | 21.09 ± 5.45 | 19.00 ± 5.50 | 21.3 ± 4.5 | 22.3 ± 3.2 | 21.5 ± 5.1 | 20.7 ± 5.1 |
| Day 56 - Negative symptoms | 21.10 ± 5.93 | 18.71 ± 4.72 | 20.4 ± 4.7 | 21.8 ± 4.2 | 19.8 ± 4.9 | 20.3 ± 5.7 |
| Day 70 - Negative symptoms | 21.20 ± 5.07 | 17.71 ± 2.75 | — | — | — | — |
| Day 84 (Week 12) - Negative symptoms | 18.90 ± 5.38 | 15.33 ± 3.08 | 20.5 ± 5.9 | 22.5 ± 4.8 | 18.6 ± 4.4 | 19.4 ± 4.8 |
| Baseline - Positive symptoms | 17.93 ± 3.99 | 19.75 ± 3.93 | 18.9 ± 4.6 | 18.0 ± 3.7 | 17.6 ± 4.2 | 17.2 ± 5.4 |
| Day 14 - Positive symptoms | 18.23 ± 4.75 | 21.30 ± 4.35 | 17.8 ± 3.8 | 18.3 ± 5.3 | 18.1 ± 3.9 | 18.0 ± 5.7 |
| Day 28 - Positive symptoms | 17.60 ± 4.77 | 19.22 ± 5.19 | 17.9 ± 4.3 | 24.3 ± 6.0 | 18.0 ± 4.9 | 17.4 ± 5.9 |
| Day 42 - Positive symptoms | 17.82 ± 4.31 | 18.75 ± 4.13 | 18.2 ± 4.8 | 22.5 ± 6.0 | 16.0 ± 4.4 | 16.2 ± 4.7 |
| Day 56 - Positive symptoms | 17.90 ± 4.93 | 20.71 ± 1.50 | 17.7 ± 5.0 | 20.5 ± 3.1 | 17.2 ± 6.1 | 15.8 ± 4.5 |
| Day 70 - Positive symptoms | 19.20 ± 2.86 | 19.29 ± 2.69 | — | — | — | — |
| Day 84 (Week 12) - Positive symptoms | 17.70 ± 5.25 | 19.67 ± 3.61 | 17.3 ± 4.5 | 21.5 ± 2.6 | 16.5 ± 4.7 | 15.5 ± 4.3 |
The BNSS is a 13-item instrument designed for clinical trials that measures the severity of the negative symptoms of schizophrenia in five domains. There are 13 items organized into 6 subscales (anhedonia, distress, asociality, avolition, blunted affect, and alogia), each rated on a 7-point scale (0-6) where 0 = absent symptoms and 6 = severe symptoms. The total score is calculated by summing the individual items (13) of each subscale and has a range of 0-78.
| Units on a scale | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Baseline | 34.79 ± 14.98 | 35.17 ± 13.68 | 36.6 ± 14.9 | 36.4 ± 6.7 | 38.1 ± 13.7 | 38.4 ± 13.8 |
| Day 14 | 35.08 ± 12.48 | 32.90 ± 13.47 | 36.1 ± 11.4 | 29.3 ± 11.1 | 34.1 ± 12.8 | 35.2 ± 12.8 |
| Day 28 | 29.90 ± 14.49 | 33.25 ± 8.94 | 32.6 ± 12.9 | 32.7 ± 7.4 | 33.1 ± 13.4 | 36.5 ± 10.3 |
| Day 42 | 34.09 ± 11.95 | 36.38 ± 14.79 | 35.1 ± 11.3 | 35.0 ± 11.8 | 35.5 ± 12.6 | 32.7 ± 13.4 |
| Day 56 | 37.40 ± 18.60 | 34.00 ± 12.12 | 30.3 ± 12.1 | 37.5 ± 16.3 | 30.8 ± 11.8 | 32.3 ± 13.6 |
| Day 70 | 33.10 ± 7.23 | 34.00 ± 15.15 | — | — | — | — |
| Day 84 (Week 12) | 30.40 ± 12.86 | 28.17 ± 20.44 | 32.7 ± 13.4 | 33.3 ± 10.6 | 29.6 ± 9.2 | 29.2 ± 12.4 |
The DPAS is a 15-item, patient-rated assessment that evaluates expectations of failures or self-defeating beliefs related to prior failed experiences as well as illness on a 7-point Likert scale (total range = 15-105) ranging from totally agree (1) to totally disagree (7).
| Units on a scale | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Baseline | 34.73 ± 13.92 | 30.25 ± 12.43 | 40.2 ± 14.6 | 40.0 ± 6.4 | 38.2 ± 15.9 | 35.9 ± 16.2 |
| Day 42 | 40.54 ± 16.37 | 27.50 ± 18.65 | 37.5 ± 14.2 | 39.3 ± 9.3 | 38.8 ± 16.2 | 36.0 ± 16.2 |
| Day 84 (Week 12) | 38.80 ± 13.42 | 16.00 ± 4.98 | 36.0 ± 15.2 | 54.3 ± 16.4 | 39.0 ± 19.9 | 32.2 ± 13.6 |
The C-SSRS is a suicide risk assessment tool used to help identify the risk of suicide.
| Number of participants | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Suicidal ideation or behavior | 0 | 0 | 1 | 0 | 2 | 1 |
| Self-injurious behavior without suicidal intent | 1 | 0 | 0 | 0 | 0 | 0 |
The ESRS-A is used to evaluate the presence and severity of extrapyramidal symptoms. Items are rated on a scale of 0 (no symptoms) to 5 (extreme symptoms).
| Units on a scale | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Akathisia Baseline | 0.07 ± 0.26 | 0.08 ± 0.29 | 0.27 ± 0.87 | 0.00 ± 0.00 | 0.27 ± 0.83 | 0.38 ± 0.98 |
| Akathisia Day 84 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.29 ± 0.94 | 0.00 ± 0.00 | 0.10 ± 0.45 | 0.10 ± 0.44 |
| Dyskinesia Baseline | 0.00 ± 0.00 | 0.33 ± 0.89 | 0.46 ± 1.95 | 0.75 ± 0.96 | 0.17 ± 0.38 | 0.63 ± 1.68 |
| Dyskinesia Day 84 | 0.10 ± 0.32 | 0.00 ± 0.00 | 0.16 ± 0.90 | 0.00 ± 0.00 | 0.15 ± 0.49 | 0.29 ± 0.72 |
| Dystonia Baseline | 0.07 ± 0.26 | 0.00 ± 0.00 | 0.24 ± 0.86 | 0.00 ± 0.00 | 0.03 ± 0.18 | 0.16 ± 0.51 |
| Dystonia Day 84 | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.26 ± 1.03 | 0.00 ± 0.00 | 0.05 ± 0.22 | 0.00 ± 0.00 |
| Parkinsonism Baseline | 0.13 ± 0.52 | 0.42 ± 1.00 | 1.03 ± 2.36 | 2.20 ± 1.92 | 2.00 ± 3.24 | 2.22 ± 4.15 |
| Parkinsonism Day 84 | 0.20 ± 0.63 | 0.33 ± 0.82 | 1.03 ± 2.87 | 0.33 ± 0.58 | 1.15 ± 2.68 | 1.00 ± 2.30 |
| ng/mL | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|
| Maximum Serum Concentration (Cmax) of RO6889450 | 157 ± 58.7 | 794 ± 40.3 | 1550 ± 43.9 |
| h*ng/mL | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|
| Area Under the Curve at Steady State (AUCss) of RO6889450 | 2980 ± 54.8 | 15100 ± 43.8 | 28600 ± 48.4 |
Collected over Up to Day 84 (Week 12). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Monotherapy (Placebo) | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| Part A: Monotherapy (150 mg) | 0/12 (0%) | 1/12 (8.3%) | 4/12 (33.3%) |
| Part B: Add-on Therapy (Placebo) | 1/37 (2.7%) | 1/37 (2.7%) | 9/37 (24.3%) |
| Part B: Add-on Therapy (45 mg) | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Part B: Add-on Therapy (150 mg) | 0/30 (0%) | 2/30 (6.7%) | 8/30 (26.7%) |
| Part B: Add-on Therapy (300 mg) | 0/32 (0%) | 0/32 (0%) | 4/32 (12.5%) |
| Event | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/15 | 1/12 | 0/37 | 0/5 | 0/30 | 0/32 |
| Rhinovirus infectionInfections and infestations | 0/15 | 0/12 | 0/37 | 0/5 | 1/30 | 0/32 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/15 | 0/12 | 0/37 | 0/5 | 1/30 | 0/32 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/15 | 0/12 | 0/37 | 0/5 | 1/30 | 0/32 |
| Accidental deathGeneral disorders | 0/15 | 0/12 | 1/37 | 0/5 | 0/30 | 0/32 |
| Event | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) |
|---|---|---|---|---|---|---|
| Lip painGastrointestinal disorders | 0/15 | 0/12 | 0/37 | 1/5 | 0/30 | 0/32 |
| Non-cardiac chest painGeneral disorders | 0/15 | 0/12 | 0/37 | 1/5 | 0/30 | 0/32 |
| Upper respiratory tract infectionInfections and infestations | 2/15 | 0/12 | 0/37 | 1/5 | 0/30 | 0/32 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/15 | 0/12 | 0/37 | 1/5 | 0/30 | 0/32 |
| Dizziness posturalNervous system disorders | 0/15 | 0/12 | 0/37 | 1/5 | 0/30 | 0/32 |
| InsomniaPsychiatric disorders | 1/15 | 2/12 | 0/37 | 0/5 | 0/30 | 0/32 |
| NauseaGastrointestinal disorders | 0/15 | 2/12 | 0/37 | 0/5 | 1/30 | 1/32 |
| NasopharyngitisInfections and infestations | 0/15 | 0/12 | 2/37 | 0/5 | 3/30 | 3/32 |
| Urinary tract infectionInfections and infestations | 0/15 | 1/12 | 0/37 | 0/5 | 0/30 | 0/32 |
| ConstipationGastrointestinal disorders | 0/15 | 1/12 | 0/37 | 0/5 | 1/30 | 0/32 |
| Age, Continuous(Years) | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 42.7 ± 9.9 | 43.3 ± 6.6 | 41.3 ± 9.7 | 41.6 ± 11.3 | 40.0 ± 9.6 | 40.9 ± 9.2 | 41.3 ± 9.3 |
| Sex: Female, Male(Participants) | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) | Total |
|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 10 | 0 | 11 | 12 | 39 |
| Male | 12 | 9 | 27 | 5 | 19 | 20 | 92 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 2 | 0 | 6 | 5 | 14 |
| Not Hispanic or Latino | 14 | 11 | 35 | 5 | 24 | 27 | 116 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Part A: Monotherapy (Placebo) | Part A: Monotherapy (150 mg) | Part B: Add-on Therapy (Placebo) | Part B: Add-on Therapy (45 mg) | Part B: Add-on Therapy (150 mg) | Part B: Add-on Therapy (300 mg) | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 8 | 0 | 6 | 4 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 12 | 9 | 11 | 5 | 7 | 10 | 54 |
| White | 2 | 3 | 16 | 0 | 16 | 18 | 55 |
| More than one race | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2018 to primary completion in Mar 2023, 51 months.
Results were first posted in Aug 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ralmitaront